IL35523A - A process for preparing butyrophenone derivatives,novel phenylbutanol derivatives and a pharmaceutical composition containing the same - Google Patents

A process for preparing butyrophenone derivatives,novel phenylbutanol derivatives and a pharmaceutical composition containing the same

Info

Publication number
IL35523A
IL35523A IL35523A IL3552370A IL35523A IL 35523 A IL35523 A IL 35523A IL 35523 A IL35523 A IL 35523A IL 3552370 A IL3552370 A IL 3552370A IL 35523 A IL35523 A IL 35523A
Authority
IL
Israel
Prior art keywords
signifies
group
alkyl
hydrogen
formula
Prior art date
Application number
IL35523A
Other versions
IL35523A0 (en
Original Assignee
Sumitomo Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP44088513A external-priority patent/JPS504672B1/ja
Priority claimed from JP1093070A external-priority patent/JPS4945872B1/ja
Priority claimed from JP3336270A external-priority patent/JPS5416504B1/ja
Application filed by Sumitomo Chemical Co filed Critical Sumitomo Chemical Co
Publication of IL35523A0 publication Critical patent/IL35523A0/en
Publication of IL35523A publication Critical patent/IL35523A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

A A PROCESS FOR PREPARING- BUTYROPHENONE DERIVATIVES, NOVEL PHENYLBUTMOL DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING- THE SAME.
The present invention relates to a process for preparing butyrophenone derivatives useful as medicines. More particularly, the invention relates to a novel and advantageous process for preparing butyrophenone derivatives represented by the general formula, £ C0CH CH CH - / (I) wherein A signifies a single or double bond linkage; R-^ signifies a hydrogen atom or a - alkyl group; ^, which is present only in case A signifies a single bond linkage, signifies a hydrogen atom, or a hydroxy!, 0·^ - alkyl or - alkoxy group; . ^ signifies a hydrogen atom, or a piperidino, pyrrolidino, morpholino, furyl, hienyl, C-^ - alkylamino, benzylamino, unsubstit ted or i substituted phenyl group having the formula, signifies a hydrogen or halogen atom, or a C1 - alkyl, - alkoxy, or trifluoromethyl group), or a group having the formula, 0 Rγ, - . g (wherein R6 signifies a hydrogen \==/ atom or a C-j - alkyl group, and each of y and Rg signifies a hydrogen or halogen atom, a Cj - alkyl, or Cj - alkoxy group): and X signifies a hydrogen or halogen atom, or a Cj - alkyl, C-j - alkoxy, or trifluoromethyl group.
In French patent 2429M there are disclosed aralkyl and hydroxyaralkyl derivatives of 4(N-arylalkanam1de/!)-piperid1nes, and the french patent 6738 M discloses hydroxyalkyl-4-substituted-piperldines. However, none of said patents teaches or suggests the subject matter of the present invention.
The butyrophenone derivatives represented by the above-said general formula (I), which are prepared by the process of the present invention, have an excellent central nervous system depressant and are useful as tranquilizers, analgesics, and sedatives. For example, ¾ -(4-hydroxy-4-p-chlorophenylpiperidino)-p-fluorobutyrophenone is known 1n the art as a substance having an excellent psychotropic activity.
The present inventors have found a novel and advantageous process for preparing these useful butyrophenone derivatives. That is, the present Inventors have found that the butyrophenone derivatives of the above-said formula (I) can be prepared very advantageously by the following reactions: wherein ^ , R-^, ILj, and X have the same meanings as mentioned above.
Accordingly, the first object of this invention is to provide a novel and advantageous process for preparing butyrophenone derivatives of the above-said general formula ( I) .
Another ob ect is to provide novel phenylbutanol derivatives useful as medicines or intermediates for medicines.
A further object is to provide a novel pharmaceutical composition.
Other objects and merits of the present invention will be apparent from the following description.
In order to attain the above-mentioned objects, the present invention provides a process for preparing butyrophenone derivatives of the general formula (I), which is characterized by reacting a phenylbutanol derivative of the general formula (II) with an oxidizing agent.
Further, the present invention provides a process for preparing butyrophenone derivatives of the general formula (I), which is characterized by reacting a benzoylpropionamide derivative of the general formula (III) with a reducing agent to form a phenylbutanol derivative of the general formula (II), and then reacting the said phenylbutanol derivative of the general formula (II) with an oxidizing agent.
Moreover, the present invention provides novel phenylbutanol derivatives represented by the general formula II exce t for the case where simultaneousl A signifies a single bond linkage, Rg . signifies a lower alkoxy groip, and signifies an afo ementioned unsubstituted or substituted phenyl group. These phenyl-bitanol derivatives are also useful as tranquilizers, analgesics or sedatives.
Examples of alkyl groups in the aforementioned general formulas (I), (II) and (III) include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, or tert.-butyl.
Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy or tert.-butoxy.
Examples of halogen atoms include fluorine, chlorine, bromine or iodine.
Examples of alkylamino grotips include methylamino, ethylamino, isopropylamino, n-butylamino or the like.
The process of the present invention is illustrated below in detail according to the sequence of reactions.
Step 1. Reduction of benzoylpropionamide In the present process, the reduction is effected in a stiitable organic solvent using various reducing agents. Examples of preferable reducing agents are complex compounds of metal hydrides, and particularly preferred is lithium aluminum hydride, diborane, or sodium borohydride—a halogenated metallic compound.
While the reducing agents can be used in a stoichiometric amount or more, the objective phenylbutanol derivatives are obtained generally in high yields. The reaction is conducted at a temperature within a range of 0°C to a "boiling point of a solvent, preferably 10° to 100°C. In case a complex compound of metal hydride is used as the reducing agent, the solvents used in the present process include diethyl ether, di-n-butyl ether, tetrahydrofuran, dioxane, methylal, N-ethylmorpholine, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether, etc.
After the reaction is complete, the excess of reducing agent present and the complex compound thereof formed are decomposed by addition of water, an alcohol, ethyl acetate or the like, and then the objective phenylbutanol derivative can be isolated or, if necessary, further purified by reerystallization, etc. If desired, the product can be converted into an acid addition salt thereof by the treatment with a mineral or organic acid. The said salt can be formed with, for example, hydrochloric, sulfuric, phosphoric, hydrobromic, thiocyanic, acetic, propionic, oxalic, citric, malic, tartaric, fumaric, maleic, succinic, glycolic, benzoic, cinnamic, p-amino-salicylic, salicylic, methanesulfonic, ascorbic acids, etc.
By the above-said procedure, phenylbutanol derivatives (II) are obtained in high yields.
Step 2. Oxidation of phenylbutanol derivative The phenylbutanol derivatives (II) obtained in the above-mentioned step 1 are then oxidized to yield butyrophenone derivatives of the general formula (I) in high yields. In the present invention, various oxidizing agents may be used. Examples of the oxidizing agents used in the present invention include manganese dioxide, chromic acid, chromates, oxygen, ozone, dimethyl sulfoxide, potassium permanganate, osmium oxide, and organic per-acids. There may be also employed Oppenauer oxidation, or photo-oxidation. The reaction is generally carried out in water or in an organic solvent at a temperature of 0° to 40°C, and lower or higher temperatures may be used. Examples of the organic solvents used in the present oxidation include petroleum ether, ether, chloroform, carbon tetrachloride, benzene, acetic acid, acetone, pyridine, ethyl acetate, etc.
The resulting objective compound of the general formula (I) can be converted, if necessary, into an acid addition salt thereof by treatment, as in step 1, with a mineral or organic acid.
By the process of the present invention there are synthesized the following compounds: l-Phenyl-4-(4-hydroxy-4-phenyl-piperidino)-1-butanol l-(p-Fluorophenyl)-4-[4-hydrox -4-(p-methylphenyl)- piperidino] -1-butanol l-(p-Fluorophenyl)-4-[4-(p-chlorophenyl)-4-hydroxypiperidino]- 1-butanol l-( p-Fluorophenyl)-4-[4-hydroxy-4-(m-trifluoromethyl- phenyl)piperidino] -1-butanol l-(p-Fluorophenyl)-4- [ -hydroxy-4-(p-methoxyphenyl)- piperidino] -1-butanol l-(p-Fluorophenyl)-4-[4-( 2-oxo-l-benzimidazolinyl)- piperidino] -1-butanol l-(p-Fluorophenyl)-4-[4-( 2-oxo-l-benzimidazolinyl)- 1, 2, 3,6-te ahydro-l-pyridyl] -1-butanol l-(p-Fluorophenyl)-4-[4-(p-chlorophenyl)-1,2,3,6- tetrahydro-l-pyridyl]-1-butanol 1-(p-Fluorophenyl)-4-[4-(p-chlorophenyl)-4-methoxy- piperidino] -1-butanol 1-( -Fluorophenyl)-4-(4-isopropylaminopiperidino)-1- butanol 1-(p-Fluorophen 1)-4-[4-etho y-4-( 2-1hien 1)piperidino]- 1-butanol 1-(p-Fluorophenyl)-4-[4-(1-piperidy1)piperidinqj-l-butanol 1-(p-Fluoropheny1)-4- 4-(4-morpholyl)piperidinoJ-1-butanol 1-( p-Chlorophenyl)-4-[4-(p-chlorophenyl)-4-hydroxy- piperidino]-1-butanol 1-(p-Bromophenyl)-4- -(p-chlorophenyl)-4-hydroxy- piperidino]-1-butanol 1-(p-Me hoxyphenyl)-4-[4-(p-chlorophenyl)-4-hydroxy- piperidino] -1-butanol l-(p-Methylphenyl)-4-[4-(p-chlorophenyl)-4-hydroxy- piperidino]-1-butanol l-(p-Trifluoromethylphenyl)-4-[p-chlorophenyl)-4- hydroxypiperidino]-1-butanol l-(p-Fluorophenyl)-4-[4-(p~chlorophenyl)piperidino]-l- butanol 1-(p-Fluorophenyl)-4-[3-methyl-4-(p-chlorophenyl)-4- hydroxypiperidino]-1-butanol Y~(4-Hydroxy-4-phenylpiperidino)-butyrophenone [4-Hydroxy-4-(p-methylphenyl)piperidino]-p-fluorobutyro- phenone Y~[4-(p-Chlorophenyl)-4-hydrox piperidino] -p-fluorobutyro- phenone Y~[4-Hydroxy-4-(m-trifluoromethylphenyl)piperidino] -p- fluorobutyrophenone ^-Q4-Hydroxy-4-(p--iiethoxyphenyl)piperidirL ] -p-fluorobutyrophenone β-[4-( 2-Oxo-l-benzimidazolinyl)piperidino]-p-fluorobutyro- phenone 7f-[4-( 2-0xo-l-b enzimidazollJtiyl)-1, 2, 3,6-tetrahydro-1- pyridyl]-p-fluorobutyrophenone ^- - (p-Chio op enyl)-4-methox piperidinoj-p-fluorobut ro- phenone ^-£4-(p-Chlorophenyl)-l, 2, 3,6-tetrahydro-l-pyridyl]-p~ fluorobutyrophenone $~( -1sopropylaminopiperidino)-p-fluorobutyrophenone J- 4-Ethoxy-4-( 2-thienyl)piperidino]-p-fluorobutyrophenone ^- 4-(l-piperidyl)piperidinoTj-p-fluorobutyrophenone - 4-(4-Morpholyl)piperidino]-p-fluorobutyrophenone )f- [4-(p-Chlorophenyl)-4-hydroxypiperidino] -p-chlorobutyro- phenone ^- 4-(p-Chlorophenyl)-4-hydroxypiperidinq]-p-bromobut rophenone J-[4-(p-Chlorophenyl)-4-hydroxypiperidino] -p-methoxy- butyrophenone ^-Q4-(p-Chlorophenyl)-4-hydro2ypiperidino] -p-methylbutyro- phenone [4_(p-Chlorophenyl)-4-hydroxypiperidino] -p-trifluoro- methylbutyrophenone $-[4-(p-Chlorophenyl)piperidino3-p-fluorobutyrophenone - 3-Methyl-4-(p-chlorophenyl)-4-hydroxypiperidino -p- fluorobutyrophenone.
As described above, the present process is an excellent commercial process because of the simplicity of procedures, high yields, etc. case R in the formula (II) is a hydrox 1 group, two hydro yl groups are contained in the molecule of the phenylbutanol derivative. When such a compound is subjected to the oxidation of step 2 of the present invention, one of the hydroxyl groups is selectively oxidized into a carbonyl group while the other hydroxyl group, i.e. the hydroxyl represented by 2, remains intact. Such a selective oxidation is an extraordinarily characteristic reaction which can not be expected from prior art.
The benzoylpropionamide derivatives of the general formula (III), which are the starting materials of the present process, are readily synthesized using easily available materials by, for example, the following reaction scheme: Rl J-O - ^ - O- j (III) (In the above formulas, A, R-^, R2, R^ and X have the same meanings as mentioned above.) Phenylbutanol derivatives of the general 2 formula (II), in the case where R is not an alkoxy groip, and acid addition salts thereof are novel and useful compounds having excellent central nervous system activity. They are quite useful as anti-anxiety, anti-psychotonic, anti-emotional, anti-convulsive, anti-psychosis or analgesic drugs.
Each of the pharmaceutically active phenylbutanol compounds of the present invention may be, e.g., incorporated, for oral administration, in tablet as the sole active ingredient. A typical tablet is constituted by from 1 to 2 per cent of a binder, e.g. tragacanth; from 3 to 10 per cent of a lubricant, e.g. talcum; from 0.25 - 1.0 per cent of a lubricant, e.g. magnesium stearate; an average dose of active ingredient; and q.s. 100 per cent of a filler, e.g. lactose. The usual oral dosage is 1 - 100 mg per os daily.
The process for preparing benzoylpropionamide derivatives of the formula (III) is illustrated below in more detail with reference to Referential Examples.
Referential Example 1 To a solution of 15 g of ^S-p-fluorobenzoyl-propionic acid and 8.0 g of triethylamine in 100 ml of tetrahydrofuran, was gradially added 8.3 g of ethyl chlorocarbonate while the reaction mixture was kept below 0°C. After being 3tirred for 25 minutes at a ° of piperidine and stirred for another 2 hours. Then the precipitate formed was filtered off and the filtrate was concentrated to dryness under reduced pressure. The residue was recrystallized from hexane to obtain 11 g of Ι- -ρ-fluorobenzoylpropionyl) piperidine, melting at 70° - 71°C.
Referential Examples 2-4 According to the procedure similar to that in Referential Example 1, there were obtained the following compounds : 1- [ -{ p-Fluorobenzoyl)propionyl]-4-(p-chlorophenyl)-4-hydroxypiperidine, m.p, 151° - 152°C . 1- [l-- (^-p-Fluorob enzoylpropionyl ) -4-piperidyl -2-oxobenzimidazoline as colorless crystals, m.p. 205" - 206^0 , l- ?-p-Pluorobenzoylpropionyl)~4-phenyl-l , 2, 3, 6-t etra-hydropyridine, m. p. 123° - 124°C.
The present invention is further illustrated below in more detail with reference to Examples, but the scope of the invention is , of course, not limited thereto.
Example 1 Step 1 Lithium aluminum hydride ( 2. 2 g) was suspended in 40 ml of tetrahydrofuran and heated to 60°C . A solution of 5.0 g of l-( ~p-fluorobenzoylpropionyl) piperidine in ml of tetrahydrofuran was added dropwise to said suspension, and heated under reflux for 6 hours with stirring. To the reaction mixture cooled in ice, was radu ll dded 20 ml of water and the reci itate was filtered off. The filtrate was concentrated to one-third in volume, and extracted with 100 ml of ether. The ether solution was washed with water and dried over anhydrous potassium carbonate, and then gaseous hydrogen chloride was introduced therein. The white precipitate formed was collected by filtration, washed with ether, and recrystallized from ethanol-ether to obtain 4.1 g of 1-(p-fluorophenyl)-4-piperidino-l-butanol hydrochloride, as a white crystalline powder melting at 158° - 159°C.
Step 2 A mixture of 2 g of 1-(p-fluorophenyl)-4-piper dino-l-butanol liberated from the hydrochloride, 20 ml of benzene, and 4 g of a fine powder of manganese dioxide was stirred for 8 hours at room temperature.
After filtration, the precipitate was washed with 20 ml of benzene. The benzene washings and filtrate were combined and concentrated under reduced pressure to obtain oily ^piperidino-p-fluorobutyrophenone (2 g in weight; infrared absorption spectrum, ) C=01678 cm""^"). The said oily product was dissolved in 20 ml of ether, and gaseous hydrogen chloride was introduced therein to saturation. The precipitate formed was recrystallized from ethanol-ether to yield the hydrochloride melting at 180° - 181°C.
Examples 2-4 In a similar manner to that of Step 1 in Example 1, there were obtained the compounds listed in Table 1.
Table 1 Examples 5-13 In a similar manner to that of step 2 in Example 1, there were obtained the compounds listed in Table 2.
Table 2 Example 14 Step 1 To a mixture of 2.0 g of lithium aluminum hydride and 50 ml of tetrahydrofuran, was gradually added a solution of 5.0 g of l-[^(p-fl\iorobenzoyl)propionyl] -4-(p- chlorophenyl)-4-hydroxypiperidine in 40 ml of tetrahydrofuran. The mixture was stirred at room temperature for one hour, and at 60°to 65°C for 4 hours. Then 15 ml of cold water was added dropwise to the reaction mixture while the mixture was kept below 20°C in an ice bath. The precipitate was filtered off and the tetrahydrofuran was removed from the filtrate by distillation under reduced pressure. The residue was kept cooled for 2 hours and the solid matter was collected by filtration, washed with water, and dried to obtain l-(p-fluorophenyl)-4-[4-(p-chlorophenyl)-4-hydroxypiperidi_no"]-1-butanol, melting at 128° - 130°C.
Step 2 To a solution of 4.0 g of l-(p-fluorophenyl)-4- 4-(p-chlorophenyl)-4-hydroxypiperidino] -1-butanol in 100 ml of chloroform was added 10 g of manganese dioxide (fine powder). And then the mixture was stirred at room temperature for 7 hours. The reaction prodict was filtered and the filtrate was concentrated to dryness under reduced presstire. The residue was recrystallized from aqueous acetone to obtain T- 4-( p-chlorophenyl)-4-hydroxypiperidino] -p-fluorobutyrophenone, melting at 150° - 151°C.
Examples 15-19 According to the procedure similar to that in Example 14, there were obtained the following compounds.
Table 3 Example 20 One gram of chromium trioxide was added with stirring to 40 ml of pyridine cooled to 0°C. The mixture was stirred at room temperature for 1 hour, and then again cooled to 0°C. Into the said mixture was added 1.1 g of l-(p-fluorophenyl)-4-^4-hydroxy-4-(p-methylphenyl)- piperidinoj-1-butanol, and the mixture was stirred for 1 hour under cooling with ice. The reaction mixture was poured into 300 ml of cold water to separate an oily substance. The oily substance is extracted with ethyl acetate, and the ethyl acetate layer was washed 4 times with, each 60 ml of water, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. The residue was recr stallized from aqueous acetone to obtain Y-(4-hydroxy-4-p-methylphenylpiperidino)-p-fluorobutyrophenone, melting at 119° - 120°C.
Example 21 Step 1 To a stirred mixture of 2.0 g of lithium aluminum hydride and 180 ml of tetrahydrofuran at room temperature, was added 4.6 g of l-[l-(^~p-fluorobenzoylpropionyl)-4-piperidyl) -2-oxobenzimidazoline portionwise over a period of about 10 minutes. The mixture was further stirred at room temperature for one hour, then gradually heated to 60°C over a period of one hour, stirred for additional 4 hours at 60° - 65°C, and then cooled in ice. To the reaction mixture was carefully added 20 milliliters of cold water, and the precipitate formed was filtered off. The filtrate was added with 6 ml of acetic acid, and the tetrahydrofuran was removed by distillation under reduced pressure. The residue was made slightly alkaline by adding a 14 aqueous ammonia, and the solid precipitated was collected by filtration, dried, and recrystallized from toluene to obtain a white crystalline powder of 1-( p-fluorophenyl)-4- 4-( 2-oxo-l-benzimidazolin 1)-piperidino] -1-butanol, melting at 160° - 161°C.
Step 2 To a stirred mixture of 4 g of 1-(p-fluorophenyl)- 4- 4-( 2-oxo-l-benzimidazolinyl) piperidino] -1-butanol and 100 ml of acetone was added dropwise a chromic acid solution (prepared from 2 g of chromic anhydride, 5 ml of water and 2 ml of sulfuric acid) under cooling with ice. The mixture was stirred over night at room temperature, poured into 600 ml of cold water and made alkaline by addition of a 10 aqueous sodium hydroxide solution.
The basic material which was separated was extracted twice with each 100 ml of chloroform and the combined extracts were washed with water and evaporated to dryness. Recrystallization of the solid residue from aqieous acetone gave ^- 4-( 2-oxo-l-benzimidazolinyl) -piperidino^-p-fluorobutyrophenone, melting at 171° -172°C.
Example 22 To a stirred solution of 2.0 g of l-(p-fluoro-phenyl)-4- [4-( 2-oxo-l-benzimidazolinyl)-1,2,3, 6-tetrahydro-1-pyridyl] -1-butanol in 60 ml of chloroform at room temperature, was added portionwise 3.2 g of a fine powder of manganese dioxide. After completion of addition, the mixture was stirred for another 2 hours at room temperature, and the precipitate was filtered off. The filtrate was concentrated to dryness under reduced pressure, and the residue was recrystallized from dioxane containing water, to obtain f-[4-( 2-oxo-l-benzimidazolinyl)-1,2,3, 6-tetrahydro-l-pyridyl] -p-fluorobutyrophe one, melting at 146° - 147. °C Example 23 In the manner similar to that in Example 22, a compound having the following structural formula was obtained: m.p. 188-191°C Example 24 Step 1 To a suspension of 2.2 g of lithium aluminum hydride in 40 ml of tetrahydrofuran was added dropwise a solution of 5.0 g of l- -p-fluorobenzoylpropionyl)-4-phenl-l, 2, 3» 6-tetrahydropyridine in 60 ml of tetrahydrofuran over a period of about 30 minutes, during which period a mild evolution of heat was observed.
After completion of the said dropwise addition, the mixture was heated under reflux with stirring for 6 hours. A mixture of 30 ml of water and 70 ml of tetrahydrofuran was added dropwise to the reaction mixture under cooling below 20°C. The precipitate formed was filtered off and the filtrate was concentrated under reduced pressure to remove the tetrahydrofuran. The residue was refrigerated for 2 hours, and the solidified substance was collected by filtration, washed with water, and recr stallized from aqueous ethanol to obtain 4.0 g of l-(p-fluorophenyl)-4-(4-phenyl-l, 2,3 ,6- etrahydro-l-pyridyl)-1-butanol, melting at 116° - 117°C. This substance was treated with methanolic hydrogen chloride to yield the hydrochloride melting at 178° - 179°C.
Step 2 To a solution of 2.0 g of l-p-fluorophenyl-4- ( -phen l-l, 2, 3, 6-tetrahydro-l-pyridyl)-1-butanol in 30 ml of benzene was added 7 g of a fine powder of manganese dioxide. The mixture was stirred at room temperature for 6 hours, and filtered. The filtrate was concentrated to dryness under reduced pressure, and the residue was recrystallized from aqueous ethanol to obtain \-( -phenyl-l,2,3,6-tetrahydro-l-pyridyl)-p-fluoro-butyrophenone, melting at 123° - 124°C, which was treated with methanolic hydrogen chloride to yield the hydro-chloride, melting at 187° - 188°C.
Examples 25-34 Following the procedure of Example 24, there were obtained the butyrophenone derivatives shown in Table 4.
Table 4

Claims (12)

CLAlMSs What wo claim ia;—
1. A process for preparing butyrophenone derivatives of the formula, signifies a single or double bond linkage; signifies a hydrogen atom or a - alkyl group , which is present only in case /{ signifies a single bond linkage, signifies a hydrogen atom, or a hydroxyl, C-^ - alkyl, or C-^ - alkoxy group; signifies a hydrogen atom, or a piperidino, pyrrolidino, morpholino, furyl, thienyl, - alkylamino, benzylamino, unsubstituted or substituted phenyl group having the formula, and signifies a hydrogen or halogen atom, or a C-^ - alkyl, G-j^ - alkoxy, or trifluoromethyl group), or a group having the formula, (wherein Rg signifies a hydrogen atom or a - alkyl group, and each of R7 and Q signifies a hydrogen or halogen atom, a - alkyl, or C-^ - alkoxy group) ; and X signifies a hydrogen or halogen atom, or a C-^ - alkyl, C-j_ - C^ alkoxy , or trifl ioromethyl group or acid-addition salts thereof, which comprises reacting a phenyHmtanol d erivative of the formula wherein , R^_, Rg , R^ and X have the same meanings as d efined above, with an oxidizing agent .
2. A process according to Claim 1 , wherein the oxidizing agent is manganese dioxide, chromic acid , chromates , oxygen, ozone, dimethyl sulfoxide, potassium permanganate, osmium oxide, or organic per-acids.
3. A process according to Claim 1 , wherein the reaction is carried out in water or in an organic solvent .
4« A process according to Claim 1 , wherein the reaction is carried out at a temperature of 0° to 40°C .
5. A process for preparing butyrophenone derivative of the formula, wnerexn /j signifies a single or double bond linkage; R^ signifies a hydrogen atom or a C-^ - C^ alkyl group ; 2, which is present only in case j signifies a single bond linkage, signifies a hydrogen atom, or a hydroxy!, C-^ - alkyl, or 0-^ - alkoxy group; signifies a hydrogen atom, or a piperidino, pyrrolidino, morpholino, furyl, thienyl, 0-j_ - alkylamino, benzylamino , unsubstituted or substituted phenyl group having the formula, (wherein each of R. and R,- signifies a hydrogen or halogen atom, or a C-^ - alkyl, 0·^ - alkoxy, or trifluoromethyl group), or a group having the formula, (where Rg signifies a hydrogen atom or a - alkyl group, and each of ^ and Rg signifies a hydrogen or halogen atom, a - (J^ alkyl, or C-^ - alkoxy group) ; and X signifies a hydrogen or halogen atom, or a C-^ - alkyl, - alkoxy, or trifluoromethyl group, or acid-addition salts thereof, which comprises reacting a benzoylpropionamide derivative of the formula, wherein A , ^ R2» and x have the same meanings as defined above, with a reducing agent to yield a phenyl butanol derivative of the formula, wherein » ¾' ^"5 ^iave "k^1*3 s me meanings as defined above, and then reacting the said phenylbutanol-derivative with an oxidising agent to yield the objective butyrophenone derivative.
6. A process according to Claim 5, wherein the reducing agent is a metal hydride complex.
7. A process according to Claim 5, wherein the reducing agent is lithium aluminum hydride, diborane or sodium borohydride-a halogenated metallic compound..
8. A process according to Claim 5, wherein the reaction of the benzoylpropionamide derivative with the reducing agent is carried out in the presence of an organic solvent.
9. A process according to Claim 5, wherein the reaction of the benzoylpropionamide derivative with the reducing agent is carried out at a temperature of 0° to 100°C.
10. A process according to any of Claims 1 to 9» wherein the butyrophenone derivative is X-[ -(p-chloro-phenyl)-4-hydroxypiperidino]-p-fluorobutyrophenone.
11. Novel phenylbutanol derivatives of the formula, and acid addition salts thereof, wherein J signifies a single or double bond linkage; signifies a hydrogen atom or a C-, - C. ally 1 group; , which is present only in case A signifies a single bond linkage, signifies a hydrogen atom, or a hydrox 1 or G-j^ - alkyl group; signifies a hydrogen atom, or a piperidino, pyrrolidino, morpholino,' furyl, thienyl, C-^ - alkylamino, benzyl- amino, unsubstituted or substituted phenyl group having the formula, (wherein each of RA and R-. signifies a hydrogen or halogen atom, or a - alkyl, 0-^ - 0 alkoxy, or trifluoromethyl group), or a group having the formula, (wherein Rg signifies a hydrogen atom or a ¾ - alkyl group, and each of R^ and Rg signifies a hydrogen or halogen atom, a C-^ - alkyl, or C-^ - alkoxy group) ; and X signifies a hydrogen or halogen atom, or a - alkyl, C-^ - alkoxy, or trifluoromethyl group.
12. A pharmaceutical composition consisting of a pharmaceutically effective amount of a phenylbutanol derivative as claimed in Claim 11, and a pharmaceutically acceptable diluent or carrier.
IL35523A 1969-10-27 1970-10-25 A process for preparing butyrophenone derivatives,novel phenylbutanol derivatives and a pharmaceutical composition containing the same IL35523A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP8617569 1969-10-27
JP44088513A JPS504672B1 (en) 1969-11-04 1969-11-04
JP968870 1970-02-03
JP1093070A JPS4945872B1 (en) 1970-02-06 1970-02-06
JP1162970 1970-02-16
JP3336270A JPS5416504B1 (en) 1970-04-17 1970-04-17

Publications (2)

Publication Number Publication Date
IL35523A0 IL35523A0 (en) 1970-12-24
IL35523A true IL35523A (en) 1973-07-30

Family

ID=27548219

Family Applications (1)

Application Number Title Priority Date Filing Date
IL35523A IL35523A (en) 1969-10-27 1970-10-25 A process for preparing butyrophenone derivatives,novel phenylbutanol derivatives and a pharmaceutical composition containing the same

Country Status (12)

Country Link
BE (1) BE757994A (en)
CA (1) CA974240A (en)
CH (2) CH545785A (en)
DE (1) DE2065426A1 (en)
DK (1) DK131147B (en)
FI (1) FI54107C (en)
FR (1) FR2070166B1 (en)
GB (1) GB1303717A (en)
IL (1) IL35523A (en)
NL (1) NL7015554A (en)
NO (1) NO137050C (en)
SE (1) SE390301B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792906A (en) * 1971-12-18 1973-06-18 Sumitomo Chemical Co ARYL-KETONES AND THEIR PREPARATION
JPS595587B2 (en) * 1974-04-18 1984-02-06 住友化学工業株式会社 Synkinabutylofenon Yudoutai Oyobi Sonoen no Seihou
HU211019B (en) * 1991-12-02 1995-09-28 Richter Gedeon Vegyeszet Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
WO2009034029A2 (en) * 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituted 4-heterocyclylpiperidines for use as cgrp antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6709169A (en) * 1967-02-17 1968-08-19

Also Published As

Publication number Publication date
GB1303717A (en) 1973-01-17
NO137050C (en) 1977-12-21
FI54107C (en) 1978-10-10
CH545287A (en) 1973-12-15
CH545785A (en) 1974-02-15
CA974240A (en) 1975-09-09
FR2070166B1 (en) 1974-02-22
DE2052537A1 (en) 1971-09-02
FI54107B (en) 1978-06-30
DE2065426B2 (en) 1979-04-05
SE390301B (en) 1976-12-13
NO137050B (en) 1977-09-12
DE2065426C3 (en) 1979-11-29
NL7015554A (en) 1971-04-29
FR2070166A1 (en) 1971-09-10
DE2065426A1 (en) 1973-07-19
DK131147B (en) 1975-06-02
DK131147C (en) 1975-11-10
IL35523A0 (en) 1970-12-24
BE757994A (en) 1971-04-01
DE2052537B2 (en) 1975-09-18

Similar Documents

Publication Publication Date Title
KR910009937B1 (en) Method of preparing piperidines
CA1340192C (en) Cyclic amine compound
US3936468A (en) Phenylbutanol derivatives
US4241071A (en) Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
EP0040639A1 (en) Isoxazole derivatives
JPS61100563A (en) 1-((aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl)-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidine acetamide and acetonitrile
US3799932A (en) Gamma-piperidinobutyrophenones
CA1120036A (en) 4-(naphthylmethyl)piperidine derivatives
US4505916A (en) Method for the treatment of psychoneurotic states by administration of derivatives of 2-(4-piperidyl)-1-(4-quinolyl)-ethanone
US4508724A (en) Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarrhythmic or hypotensive activity
US4478837A (en) 3-Hydrazino cycloalkyl[c]pyridazines as antihypertensive agents
US4021552A (en) 10-[ω-(BENZOYLPIPERIDINYL)ALKYL]PHENOTHIAZINES
CA1045139A (en) Process for the preparation of tetrahydropyridine and piperidine derivatives
DE2162011A1 (en) New derivatives of isoindoline, their preparation and medicinal compositions containing them
US4148796A (en) γ-Piperidinobutyrophenones
IL35523A (en) A process for preparing butyrophenone derivatives,novel phenylbutanol derivatives and a pharmaceutical composition containing the same
US4324791A (en) Heterocyclic antidiarrheal compositions & methods of use
IE50015B1 (en) 3-methyleneazetidine derivatives
JPS6157311B2 (en)
CA2220140C (en) (2-morpholinylmethyl)benzamide derivatives
US3485835A (en) 2-benzoyl-3-tertiaryamino alkoxy benzofuran derivatives
JPH05502235A (en) imidazoles
US4009275A (en) Phenoxypropylamine derivatives
US3786059A (en) 1,2,3,6-tetrahydro-4-pyridylmethyl carboxylates
US3637675A (en) Piperidyl and pyridyl compounds